However, in Pten-deficient prostate cancer models, deletion of the p110β, but not p110α, subunit of PI3K was able to inhibit tumorigenesis and AKT activation [89], implying the direct effect of p110β-PI3K on AKT activation. Here, PIK3CB is linked to prostate cancer.